Rami S. Komrokji, MD

Rami S. Komrokji, MD, is a professor of medicine and Oncologic Sciences at the University of South Florida College of Medicine, and vice chair of the Malignant Hematology Department at Moffitt Cancer Center, n Tampa, FL.

Articles

Dr Komrokji on the Importance of Establishing a Clinical Consensus Regarding the Use of Molecular Testing in MDS

February 26th 2025

Rami Komrokji, MD, discusses the importance of establishing a clinical consensus to standardize the use of molecular testing in myelodysplastic syndromes.

Dr Komrokji on Ongoing Investigations With Luspatercept in MDS

November 3rd 2023

Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.

Dr. Komrokji on the Changing Landscape of AML

September 7th 2018

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).

Dr. Komrokji Discusses Molecular Testing for MDS

June 23rd 2017

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses molecular testing for patients with myelodysplastic syndromes (MDS).

Dr. Komrokji on Risk Stratification of Therapy-Related MDS

May 1st 2015

Rami S. Komrokji, MD, clinical director, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, discusses a study that examined risk stratification of therapy-related MDS.

Dr. Komrokji on Optimizing MDS Management

April 14th 2015

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).

Dr. Komrokji on MDS Risk Factors and Preventative Measures

March 6th 2015

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the risk factors of developing myelodysplastic syndromes (MDS) and any preventative measures.

Dr. Komrokji on Pacritinib for the Treatment of Myelofibrosis

April 21st 2014

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.